Barclays initiated coverage of Claritev with an Overweight rating and $28 price target. With the shares down 70% from the peak in September, Claritev's risk/reward skews positive, the analyst tells investors in a research note. The firm believes the company's recent operational momentum is underappreciated in consensus estimates and finds the stock's valuation attractive at current levels.
